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ABSTRACT 
The liver represents a frequent site for metastatic disease, in addition to being a site for primary cancer. Hepatic 
metastases from certain neoplasms, such as colon, neuroendocrine, melanoma and gastrointestinal stromal tumour have a 
distinct predilection to metastasize the liver, which in many cases may represent the only or the dominant site of disease. 
In these circumstances, cytoreduction via surgery or in situ ablative techniques aims to influence the natural history of 
the disease progression and improve clinical outcomes.  
Liver directed therapy utilising yttrium-90 microspheres represents a recently introduced in situ multidisciplinary 
cancer therapy that has caught the attention of many physicians faced with the challenges of treating these complex 
patients. Although similar to other forms of trans-arterial liver directed therapy, there are discrete differences and 
potentially fatal treatment consequences unique to this therapy. This objective of this review article is to provide the 
reader a basis for understanding the therapeutic principles, patient exclusion criteria, pre and post therapy investigations 
and salient clinical results in the two most commonly treated disease types; metastatic colorectal cancer and 
hepatocellular cancer. © 2006 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Metastatic colorectal cancer and hepatocellular 
cancer are amongst the commonest causes of cancer 
mortality worldwide. A total of 437,000 worldwide 
deaths are estimated for colorectal cancer, making it the 
third most important cause of cancer mortality overall [1]. 
Hepatocellular cancer is the fourth most common cause 
of death from cancer and rapidly increasing in incidence 
in the United States [2]. Surgical resection with curative 
intent with or without adjuvant chemotherapy for 
colorectal cancer is considered to offer the highest 
survival rates that range from 30-58% at five years  [3,4]. 
Recurrent, most often unresectable disease in the hepatic 
remnant contributes significantly to this inability to 
achieve long term cure rates for colorectal cancer 
patients [5]. Five year survival estimates range between 
30-50% following hepatic resection and less than 20% 
following transplantation for hepatocellular cancer [6].  
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Since mortality and morbidity in this patient group 
is directly related the presence of hepatic disease, the 
local application of in-situ cytoreductive therapies may 
favourably alter the natural history of tumour progression. 
These therapies can be broadly categorised as those 
applied via the transcapsular or trans-vascular routes. 
The myriad of therapies that exploit the trans-arterial 
route are based on the premise that metastatic tumours 
receive their blood supply from the arterial rather than 
the portal circulation, unlike normal hepatocytes  [7]. 
Hepatic artery injection allows preferential delivery of 
material to the peri-tumoural vascular plexus  [8]. A 
suspension of particles injected via the hepatic artery, 
such as microspheres of appropriate diameter, will 
preferentially lodge in the peri-tumoural vessels, a 
process termed embolisation.  
Radiation is tumouricidal if sufficient tumour doses 
can be delivered selectively without damaging adjacent 
normal tissue in the process. External beam hepatic 
radiotherapy is limited in efficacy in the presence of 
multifocal or large tumours in the liver since the 
radiation exposure of normal hepatocytes results in liver 
insufficiency before achieving tumour kill  [9]. 
Brachytherapy, wherein the therapeutic radiation source 
is in physical contact with the tumour, circumvents the 
limitation of non-selectivity of extracorporeal 
radiotherapy. The utilisation of this effective technology, 
however, is largely limited, by the frequent requirement 
of direct visualisation of the liver that is traditionally 
achieved intra-operatively and is technically prohibitive 
in the presence of multifocal disease.  
From the above discussion, it is evident that the 
altered arterial supply to hepatic tumours could 
potentially be exploited to deliver lethal doses of 
radiation. A high energy radiation source combined with 
an appropriately sized trans-hepatic arterial administered 
embolic microscopic particle would allow radiation to be 
delivered preferentially to the tumour [10]. A β-emitter, 
   
(a) (b) 
Figure 1  (a) Electron micrograph; SirSpheres, resin. (b) Electron micrograph; Therasphere, glass. 
 
 
     
(a) (b) (c) 
Figure 2  Planar nuclear medicine scintigraphy. Patterns of distribution of Tc99m MAA following hepatic arterial 
delivery (bold arrow-liver; thin arrow- lung; double arrows- gut). (a) Normal distribution with no 
extrahepatic activity and no significant hepato-pulmonary shunting. (b) Excessive hepato-pulmonary 
shunting. A 26% shunt fraction precluded treatment in this patient with hepatocellular carcinoma. (c) 
Significant gastrointestinal reflux. Treatment is precluded if this phenomenon is not corrected. 
Incidentally is also noted of excessive hepatopulmonary shunting. 
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such as yttrium-90, would create a zone of high radiation 
exposure confined to the vicinity of the tumour while 
maintaining non-tumourous hepatic parenchymal 
exposure to tolerable levels. This forms the premise for 
the selective internal radiation therapy or SIRT. Millions 
of microspheres, measuring about 30µ in diameter 
incorporating yttrium-90, are injected via a hepatic 
arterial catheter to the arterial supply of the tumour. 
SIRT is a technique that allows high average doses of 
radiation (200 to 300 Gy) to be given to liver tumours 
with minimal serious effect on the nontumourous liver  
[11].  
BIOPHYSICAL PROPERTIES OF YTTRIUM-90  
Yttrium-90 (Y90), a pure β emitter is produced by 
neutron bombardment of yttrium-89 in a reactor. Y90 has 
a physical half-life of 64.2 hours (2.67 days) and decays 
to stable zirconium 90. The average energy of the 
emissions from the Y90 is 0.9367 MeV, with an 
average/maximal penetration range of 2.5 mm and 11mm 
respectively in tissue. One gigabecquerel (27 mCi) 
delivers a total absorbed radiation dose of 50 Gy/kg. In 
therapeutic use in which the isotope decays to infinity, 
94% of the radiation is delivered in 11 days. Y90 is the 
active moiety in a variety of targeted radio-
immunotherapies used in the treatment of a variety of 
solid organ and hematological malignancies. Two Y90 
microsphere products are commercially available (Figure 
1), TheraSpheres® (MDS Nordion, Ottawa, Canada) and 
SIR-Spheres
® (SIRTEX Medical, Sydney, Australia) and 
vary in their physical composition and radioactivity 
levels (Table 1). 
MULTIDISCIPLINARY TREATMENT APPROACH 
In order to deliver Y90 microspheres safely and 
effectively, harnessing the skills of many different 
specialties are paramount. In the United States, 
interventional radiologists, surgical oncologists, medical 
oncologists, nuclear medicine physicians, radiation 
oncologists, medical physicists and radiation safety 
experts bring invaluable expertise to the treatment 
process. It is imperative that this multidisciplinary team 
confirms the presence of liver dominant unresectable 
disease before proceeding. In general, a performance 
status (ECOG ≤ 1) is correlated with reasonable life 
expectancy.  
CONTRAINDICATIONS 
There are two absolute contraindications for liver 
directed therapy with Y90 microspheres; excessive 
hepatopulmonary and demonstrable gastrointestinal 
shunting that can lead to fatal and morbid complications 
of radiation pneumonitis and gastric ulceration 
respectively. Fortunately the likelihood of developing 
these complications can be detected before definitive 
treatment by utilising Tc99m MAA as a surrogate that 
mimics the distribution of the Y90 microspheres 
(Figure 2). 
Hepatopulmonary Shunting: Pathologic 
arteriovenous communications develop within hepatic 
neoplasia. Microspheres injected into the hepatic artery 
pass through the tumour via these shunts and are carried 
by the venous return to the heart via the hepatic veins 
and eventually embolise within terminal pulmonary 
arteriolar branches. As the magnitude of shunt increases, 
proportionately larger numbers of radioactive 
microspheres can reach the lungs causing clinically 
significant radiation pneumonitis. Maintenance of lung 
exposure below a mean dose of 30Gy avoids this 
complication [12]. The magnitude of this shunting 
phenomenon is calculated by a quantitative assessment 
of the ratio of the gamma emission count in the lung to 
that in the liver corrected for background. This numerical 
value assists in activity modification when the resin 
microspheres are used. 
Gastrointestinal Tract Deposition: Numerous 
named and unnamed arteries that supply the adjacent 
gastrointestinal tract arise normally and in a variant 
fashion from the hepatic arteries. The most common of 
these arteries are the gastroduodenal and right gastric. 
During the delivery process, microspheres may 
inadvertently reflux into these vessels resulting in their 
embolisation into the gastrointestinal submucosal 
visceral arterioles. By virtue of the combined ischemia 
and radiation effect, varying degrees of inflammation 
and ischemia ensue resulting in an ulcerative diathesis 
that is frequently treatment refractory. These vessels are 
therefore prophylactically coil embolised at their origin 
at the time of the performance of the Tc-99m-MAA 
shunt study thereby occluding the avenue for 
microsphere transit to these extrahepatic locations and 
reducing the incidence of this complication [13].  
PRE- THERAPY INVESTIGATIONS & THERAPY PLANNING 
Lab Analysis 
Serum chemical analyses also are performed to 
evaluate hepatic and renal function, traditionally 
measured by serum bilirubin and creatinine respectively. 
The presence and magnitude of elevation of tumour 
markers specific to the tumour type being treated are 
ascertained.
 By consensus, an elevated serum bilirubin 
level is
  considered a relative contraindication to 
treatment with Y90 microspheres.
  In the presence of 
renal insufficiency, care must be taken to
  avoid or 
minimize the use of iodinated contrast material. 
Treatment with Y90 microspheres must be based on 
cross-sectional images and arteriograms in the individual
 
patient. The work-up should include CT or MR imaging 
of the liver for assessment of tumoural and non-tumoural
 
volume, portal vein patency, and extent of extrahepatic 
disease.  
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Pre-procedural Cross Sectional Imaging with CT or MRI  
A triple phase CT to delineate the geographical 
distribution, the volume and the partition between 
hepatic parenchyma and tumour is essential in therapy 
planning (Figure 3). Adjunct information on portal vein 
patency and aberrant hepatic arterial anatomy is obtained. 
Distribution of the disease is typically characterised as 
unilobar or bilobar, however the correlation of tumour 
with hepatic arterial supply is variable and can only be 
ascertained with arteriography. Ascites indicates poor 
hepatic reserve or peritoneal metastasis, both of which 
have a poor prognosis. 
Arteriographic Assessment and Hepatic Arterial 
Injection of Tc 99m MAA 
  Arteriography is essential to map the hepatic 
arterial supply from the celiac and the superior 
mesenteric artery and is the single most important test to 
exclude preventable complications. Using a percutaneous 
inserted catheter, the hepatic arteries are accessed and the 
supply to the liver and the adjacent gastrointestinal tract 
is identified. Once identified, these gastrointestinal tract 
arteries are coil embolised to ensure prevention of reflux 
of microspheres into the gut (Figure 4). When such 
arteries are not confirmed arteriographically, the hepatic 
arterial infusion of 5 mCi of Tc-99m-MAA assists to 
identify occult extrahepatic perfusion. This is manifested 
by extra-hepatic scintigraphic activity on nuclear 
medicine imaging. The culprit artery can usually be 
retrospectively identified on the angiogram and then 
embolised before the Y90 microsphere delivery 
(Figure 5). 
Y90 MICROSPHERE TREATMENT 
Solitary or multiple lesions distributed in a lobe or 
both lobes can be treated with single and multiple 
microsphere treatments successfully. Nomenclature for 
the current convention for whole liver treatment by first 
treating one lobe and then the other in 4-6 weeks is 
termed “sequential” or “lobar” delivery; as opposed to 
the whole liver at one setting in which case it is termed 
‘bilobar’ in the absence of a lobectomy. The current 
practice in the United States is to allow a 4-6 week 
interval between infusions if treatment was intended to 
be delivered sequentially to allow for recovery after any 
treatment related toxicities. 
ACTIVITY DETERMINATION 
Y90 microspheres are unlike a traditional 
radiopharmaceutical or brachytherapy device and share 
the characteristics of both. At present the dose 
calculation methodology described in the package insert 
is recommended, however improvements in dosimetry 
represent an area of intense investigation [14]. CT 
treatment planning with reconstruction of the liver 
volumes assists to calculate the required activity for 
treatment.  
Glass Y90 Microsphere Activity Calculation & 
Delivery: The dose determination for glass microspheres 
is based on a nominal average target dose (150 Gy/kg), 
and the patient's liver mass is determined from the CT 
data and assumes the uniform distribution of the 
microsphere throughout liver volume as:
  
() ( )( )
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In this equation, A is the activity, D is the nominal 
target dose, and M is the mass of the targeted liver tissue. 
Resin Y90 Microsphere Activity Calculation and 
Delivery: Resin microspheres are received in a vial as a 
3 GBq dose, and the individual medical centers remove 
the prescribed activity. This process differs from that for 
glass microspheres where a predetermined dose is 
delivered to the facility. Due to the higher specific 
activity with glass microspheres and therefore the 
relative low volume of the spheres per dose, embolic 
occlusion of the parent artery has not been observed 
arteriographically. However, the prescribed activity of 
resin spheres cannot always be delivered completely [15] 
due to embolic arterial occlusion. In these instances, the 
residual activity in the delivery vial is measured and the 
delivered dose is the difference between the prescribed 
and the residual dose. The manufacturer recommends 
one of the two methods for activity determination for the 
resin microsphere; the Body Surface Area method (BSA) 
and the Empiric Method (EM). However, most 
experienced practicing physicians recommend the use of 
the BSA for resin microsphere dose calculation since the 
delivered dose more closely resembles the activity 
calculated by the BSA methodology. 
Figure 3  Pre-Y90 microsphere therapy planning evaluation in a 
58 year old female with hepatic metastatic colorectal 
cancer. Contrast enhanced axial CT scan demonstrates 
numerous bilobar low attenuation lesions consistent 
with metastases. Note patency of the portal vein. 
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 (g)  
Figure 4  58 year female with hepatic metastatic colorectal cancer undergoing pre-treatment therapy planning 
arteriography and embolisation of vessels supplying the gastrointestinal tract. (a)  Celiac  Arteriogram 
with variant anatomy; showing Splenic artery (thin arrow) ; Common hepatic artery (bold arrow) and 
the variant Gastrohepatic trunk (arrow heads). (b) Right Hepatic Arteriogram; Catheter tip in right 
hepatic artery(bold arrow); Right gastric artery (arrow heads) could not be selectively catheterised for 
embolisation. (c) GastroHepatic Trunk Arteriogram; Left gastric artery (bold arrow)anastomosing with 
right gastric artery (arrowheads) along the lesser curvature of the stomach ; note left hepatic artery (thin 
arrow) supplying the left lobe of liver. (d) Left Gastric Arteriogram; Selective 3 Fr microcatheter in the 
left to right gastric artery arcade(thin arrow); Note reflux into the right hepatic artery at the origin of the 
vessel (bold arrow). (e) Right Gastric Artery embolisation; two 3 mm fibred platinum microcoils 
deployed from origin of right gastric artery. (f) Gastroduodenal arteriogram; selective 3 Fr 
microcatheterisation of origin in preparation for embolisation. (g) Right Hepatic Arteriogram following 
embolisation of the right gastric artery; Gastroduodenal artery (arrow heads) demonstrating absence of 
flow to the gastrointestinal tract; Note the diffuse hypervascular hepatic metastases (arrows). 
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Secondary gamma emission, Bremsstrahlung, scans 
are possible due to the interaction of the high energy 
Beta emission interacting with matter. Unfortunately, 
such Bremsstrahlung emissions represent a broad 
spectrum of energy emissions rendering relatively poor 
point to point discrimination. Currently the planar and/or 
SPECT images obtained from such an acquisition are 
mostly qualitative and allow the operator to discern the 
relative distribution of the Y90 microspheres within the 
liver. Extrahepatic activity may warn clinicians of 
impending gastrointestinal complications and serve as a 
quality assurance tool (Figure 6). 
POST TREATMENT COURSE 
The most common side effect following treatment is 
mild to moderate fatigue and abdominal pain generally 
   
(a) (b) 
   
(c) (d) 
Figure 5  67 year old male with hepatic metastatic colorectal cancer undergoing pre-treatment hepatopulmonary 
shunt evaluation. (a) Proper Hepatic Arteriogram; Tc99 MAA was injected via a microcatheter placed in 
the proper hepatic artery (arrow) following coil embolisation of the gastroduodenal artery; Note 
opacification of the patent right gastric artery (arrow heads). (b) Planar thoracoabdominal scintigraphy 
following hepatic arterial injection of Tc99 MAA demonstrates predominant left lobe hepatic activity 
only (bold arrow) and absence of extrahepatic activity (thin arrow). (c) SPECT images (a) demonstrate 
activity corresponding to the CT (b) images of the left lobe of the liver (bold arrow) and in the stomach 
(thin arrow) not noted on the planar image. 
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lasting less than 2 weeks. Nausea and vomiting are less 
common and if severe may be a harbinger for a more 
gastrointestinal deposition. Patients are usually seen in 
clinic weekly or fortnightly for a month and then once 
every month. At the time of clinic visits complete blood 
count, serum tumour markers and liver function tests are 
assayed. Cross sectional imaging with CT/MRI is 
performed between 60-90 days following treatment to 
avoid radiation therapy tumour edema as erroneously 
being interpreted as progression. These decrease 
attenuation changes in the hepatic parenchyma may be 
noted on CT and are largely reversible  [16]. 18F-
fluorodeoxyglucose Positron Emission Tomography 
(PET) scans may be of use in cases of discordance where 
tumour markers are not elevated and CT scans suggest 
progression or to distinguish the site of progression in the 
presence of extra-hepatic disease when not evident by 
other standard means  [17]. 
CLINICAL APPLICATIONS 
Early studies demonstrated the feasibility of Y90 
microsphere therapy for a variety of disease types 
[18,19].Y90 microsphere therapy have since been 
applied principally for the treatment of unresectable 
hepatic metastatic colorectal and hepatocellular 
carcinoma.  
One of the first systematic application towards the 
treatment of a specific tumour type was seen for 
colorectal cancer  [20]. The application of Y90 resin 
microspheres to a patient population with hepatic 
colorectal metastases demonstrated favorable responses, 
augmented with the addition of hepatic arterial 5FU 
[21,22]. Encouraged by these results, a phase III trial in 
patients with laparotomy proven hepatic-only metastatic 
disease and resected primary was performed. In this 
pivotal trial, patients were randomised to receive intra-
arterial FUDR with or without a single dose of the resin 
microspheres [23]. The results demonstrated a benefit in 
all clinical indices favoring the combination therapy, 
specifically a time to tumour progression of 15.9 versus 
9.7 months (p<0.01) and formed the basis for FDA 
approval in the US. An important lesson was learnt 
during this trial; the majority of patients developed extra-
hepatic disease that adversely affected survival and this 
observation was supported by a separate large clinical 
experience  [24]. Furthermore, with the introduction of 
irinotecan and oxaliplatin with systemic 5 FU, liver 
directed therapy with intra-arterial FUDR was no longer 
the standard of care at the time of trial completion.  
In order to address these shortcomings, a phase II 
randomised trial and two phase I trials that combined 
systemic 5 FU/LV and the 5 FU based regimens of 
oxaliplatin and irinotecan respectively, were performed 
with enrollment in Australia and Europe. In the 
randomised phase II trial, responses were significantly 
augmented with the addition of the Y90 microspheres (8 
PR versus 0 PR) [25]. The phase I trials unequivocally 
demonstrated that these systemic therapies could be 
safely combined. Furthermore such combinations were 
within the dose ranges administered in clinical practice 
and generated robust responses (PR + CR of 90% with 
FOLFOX-4 regimen)  [26, 27]. 
In the United States however, the application of this 
therapy has been relegated to treating patients who have 
failed multiple chemotherapy regimens most often as a 
single agent and then without a fixed combinatorial 
chemotherapy regimen (Figure 7). Responses in this 
highly pre-treated population have been demonstrated, 
but as expected, are significantly lower than the chemo-
naïve population [15]. 
HEPATOCELLULAR CARCINOMA 
The other major therapeutic area that has been used 
with Y90 microsphere therapy has been in the treatment 
of unresectable hepatocellular carcinoma (HCC). 
Extensive experience has been gained in the treatment of 
HCC with resin microspheres in Asia and with glass 
spheres in the United States.  
Figure 6  Bremsstrahlung imaging assists in confirming 
successful targeting of hepatic metastatic deposits from 
carcinoid tumour. Representative axial, coronal and 
sagittal CT images(first column), SPECT images 
(second column) and SPECT/CT fusion images (third 
column) obtained with a dual-modality imaging system) 
Hawkeye GE Medical Systems, Milwaukee, Wis) show 
selective activity in the left hepatic lobe (arrow) 
approximately 24 hours after intraarterial infusion of 
90Y- bearing resin microspheres at a dose of 23.9 mCi 
(884.3 MBq). 
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In Asia, Y90 resin microspheres as an effective 
treatment option was first delineated by an 18 patient 
phase I/II trial and supported by a observational study in 
71 patients conducted by the same group. These studies 
found that tumour response and clinical benefit was 
proportional to the dose delivered; patients receiving 
>120 Gray survived 55.9 weeks compared with 26.2 
weeks for those patients that received <120 Gray. Repeat 
treatments with Y90 microspheres provided additional 
survival benefits [28,29]. A Canadian study published in 
2000 reported on 22 patients to determine response 
parameters, survival and toxicity after intra-arterial 
injection of 
90Y glass microspheres [30]. 20 were 
evaluated for efficacy including 9 patients who were 
Okuda stage I and II, and 11 patients who were Okuda 
stage III. The median dose delivered was 104 Gy (range 
45-145 Gy). Interestingly the median survival of 54 
weeks (range 7-180 weeks) and the trend for enhanced 
survival with higher doses (> 104 Gy) was similar to the 
results seen for resin microspheres. 
Several retrospective patient studies have emerged 
from the centers treating with glass Y90 microspheres in 
the USA. In an analysis by Carr et al. in 65 patients, 38% 
had partial responses while the median survival duration 
for Okuda Stage I and II patients was 649 and 302 days 
respectively [31]. Geschwind reported on 80 patients 
from a relatively large database of 121 patients who were 
treated with glass microspheres  [32]. Patients were 
   
(a) (b) 
Figure 7  Partial response to Y90 microsphere therapy with the use of 1.61 GBq glass microspheres in an 83 yr 
old man with metastatic colorectal cancer; Contrast enhanced CT scan (a) before treatment demonstrates 
a low attenuation area in the right lobe of the liver (arrow) consistent with a metastasis with (b) 
significant reduction in size 12 months after treatment. 
 
 
   
(a) (b) 
Figure 8  Portal vein invasion from right lobe hepatocellular carcinoma; (a) before and (b) after treatment with 
2.39 GBq glass microspheres in a 72 yr old man. A partial response with regression of the tumour 
thrombus (arrows) is noted. Complete normalisation of tumour marker (AFP) was obtained. 
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staged using the Child-Pugh, Okuda, or Cancer of the 
Liver Italian Program (CLIP) scoring systems. Survival 
was found to be 628 and 324 days for Okuda I (68%) and 
II (32%) patients respectively. Data from an in-depth 
subset analysis in 121 patients elucidated factors that 
predicted high 3-month mortality. These included 
infiltrative tumour, liver replacement by tumour ≥ 70%, 
elevation in liver enzymes (ALT/AST) ≥ 5 x ULN, a 
combination of tumour volume ≥ 50% and albumin < 3 
g/dL, bilirubin elevation ≥ 2 mg/dL [33]. Y90 
microsphere treatment has resulted in the downstaging of 
non-resectable disease to either be treatable by 
transplantation, resection or RFA [34] or transplant  [35] 
(Figure 8). 
In summary, the tumours treated with Y90 
microspheres have responded to therapy. This is 
evidenced by reduction in tumour volume and markers, 
ability to convert to a resectable status, and 
improvements in the time to tumour progression. 
However, there are many unanswered critical questions; 
who would be the ‘optimal’ patient? Should the radiation 
dose be fractionated, and at what dose and frequency? 
Does a dose response to tumour volume correlation exist? 
Can other newly developed systemic therapies be 
integrated safely? If so, what sequence should the 
therapy be initiated? Randomised clinical trials and 
registry data will assist answering these important 
questions. 
TOXICITIES 
The incidence of complications is low if patient 
selection is appropriate and delivery technique is 
meticulous. Post treatment fatigue occurs uniformly with 
varying degrees of severity and is almost always 
transient lasting 10-14 days. Abdominal pain, nausea and 
vomiting are common but manageable via conservative 
means. Severe symptoms are relatively uncommon and 
should alert the clinician about possible extrahepatic 
microsphere deposition and consequences thereof.  
Pancytopenia that had been reported in the earliest 
version of the Y90 microsphere has not been reported 
with the newer agents that are in current clinical use [19]. 
Radiation pneumonitis following lung exposure can 
occur when the dose to the lung exceeds 30Gy [12]. As a 
testament to the validity of utilising Tc99m MAA scan to 
calculate potential lung exposures, in over 3000 doses 
administered in the US, no cases of this complication 
have been reported. Radiation gastritis and 
gastrointestinal ulceration occur in less than 10% of 
cases; the vast majority of such cases have been managed 
conservatively without sequelae [13]. Gall bladder wall 
edema is a common finding following treatment, but 
cholecystitis requiring a cholecystectomy is rare [36]. 
Radiation induced liver disease (RILD), erroneously 
called radiation hepatitis, a form fruste of hepatic veno-
occlusive disease. This presents clinically as a triad of 
hepatomegaly and anicteric ascites. Steroids have been 
the mainstay of therapy and have a poor and variable 
success at altering the natural history of the disease 
process and in most instances hepatic insufficiency 
associated morbidity ensues. Fortunately the reported 
incidence of RILD is low. Translation of dosimetry 
research may eventually mitigate the incidence of this 
entity.  
CONCLUSION 
Y90 microspheres represent an intriguing therapy 
for the treatment of liver cancer. However, the utility of 
Y90 microsphere therapy remains to be determined 
within the context of the other currently available 
therapies. Standardisation of dosimetry and treatment 
techniques, achievable only in the robust randomised 
clinical trials, are necessary to arrive at conclusions that 
support clinical effectiveness. Registry data will be 
necessary to provide guidance on therapeutic 
effectiveness and for disease types for which clinical 
trials are not historically feasible due to their low 
incidence and for many patients who do not meet 
traditional eligibility criteria. Such efforts are underway. 
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Table 1  Characteristics of Microspheres 
Parameter Resin  Glass 
Trade name  Sir-Spheres  TheraSphere 
Diameter  22 ± 10µm  32 ± 10 µm 
Specific Gravity  1.6 g/dl  3.6 g/dl 
Activity per Particle  50 Bq  2500 Bq 
Number of microspheres per averaged 
administered activity  40 – 80 million  1.2 – 8 million 




Table 2 Contraindications 
Contraindication Criterion 
Absolute  Exaggerated hepatopulmonary shunting 
Absolute  Propensity for gastrointestinal reflux of spheres 
Absolute Pregnancy 
Absolute  Concomitant Capecitabine therapy (SIR-Spheres) 
Relative  Prior hepatic radiotherapy 
Relative Portal  hypertension 
Relative  Complete portal vein thrombosis 
Relative Hepatic  insufficiency 
Relative Renal  insufficiency 
 
10 